Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy
- PMID: 29158215
- PMCID: PMC5777304
- DOI: 10.1161/CIRCULATIONAHA.117.030792
Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by ventricular arrhythmias and an increased risk of sudden cardiac death. Although structural abnormalities of the right ventricle predominate, it is well recognized that left ventricular involvement is common, particularly in advanced disease, and that left-dominant forms occur. The pathological characteristic of ARVC is myocyte loss with fibrofatty replacement. Since the first detailed clinical description of the disorder in 1982, significant advances have been made in understanding this disease. Once the diagnosis of ARVC is established, the single most important clinical decision is whether a particular patient's sudden cardiac death risk is sufficient to justify placement of an implantable cardioverter-defibrillator. The importance of this decision reflects the fact that ARVC is a common cause of sudden death in young people and that sudden death may be the first manifestation of the disease. This decision is particularly important because these are often young patients who are expected to live for many years. Although an implantable cardioverter-defibrillator can save lives in individuals with this disease, it is also well recognized that implantable cardioverter-defibrillator therapy is associated with both short- and long-term complications. Decisions about the placement of an implantable cardioverter-defibrillator are based on an estimate of a patient's risk of sudden cardiac death, as well as their preferences and values. The primary purpose of this article is to provide a review of the literature that concerns risk stratification in patients with ARVC and to place this literature in the framework of the 3 authors' considerable lifetime experiences in caring for patients with ARVC. The most important parameters to consider when determining arrhythmic risk include electric instability, including the frequency of premature ventricular contractions and sustained ventricular arrhythmia; proband status; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or a mutation in TMEM43; and the patient's willingness to restrict exercise and to eliminate participation in competitive or endurance exercise.
Keywords: arrhythmogenic right ventricular dysplasia; death, sudden, cardiac; defibrillators, implantable; risk assessment; syncope.
© 2017 American Heart Association, Inc.
Conflict of interest statement
Conflict of Interest Disclosure:
Dr Corrado and Dr Marcus have no conflicts of interest to declare.
Figures
Similar articles
-
Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators.J Cardiovasc Electrophysiol. 2018 Oct;29(10):1396-1402. doi: 10.1111/jce.13668. Epub 2018 Jun 27. J Cardiovasc Electrophysiol. 2018. PMID: 29894017
-
Arrhythmogenic Cardiomyopathy.Circ Res. 2017 Sep 15;121(7):784-802. doi: 10.1161/CIRCRESAHA.117.309345. Circ Res. 2017. PMID: 28912183 Review.
-
Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.J Am Heart Assoc. 2017 Jun 6;6(6):e006242. doi: 10.1161/JAHA.117.006242. J Am Heart Assoc. 2017. PMID: 28588093 Free PMC article.
-
Phenotypic expression is a prerequisite for malignant arrhythmic events and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy.Europace. 2016 Jul;18(7):1086-94. doi: 10.1093/europace/euv205. Epub 2015 Jul 2. Europace. 2016. PMID: 26138720
-
Risk stratification for sudden death in arrhythmogenic right ventricular cardiomyopathy.Expert Rev Cardiovasc Ther. 2015 Jun;13(6):653-64. doi: 10.1586/14779072.2015.1043891. Epub 2015 May 6. Expert Rev Cardiovasc Ther. 2015. PMID: 25947965 Review.
Cited by
-
Endurance Training Provokes Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Heterozygous Desmoglein-2 Mutants: Alleviation by Preload Reduction.Biomedicines. 2024 Apr 30;12(5):985. doi: 10.3390/biomedicines12050985. Biomedicines. 2024. PMID: 38790949 Free PMC article.
-
A Heterozygous Phospholamban Variant (p.R14del) Leads to Left Ventricular Involvement and Heart Failure Phenotypes in Arrhythmogenic Right Ventricular Cardiomyopathy.Phenomics. 2024 Jan 29;4(1):13-23. doi: 10.1007/s43657-023-00126-w. eCollection 2024 Feb. Phenomics. 2024. PMID: 38605909
-
AAV9:PKP2 improves heart function and survival in a Pkp2-deficient mouse model of arrhythmogenic right ventricular cardiomyopathy.Commun Med (Lond). 2024 Mar 18;4(1):38. doi: 10.1038/s43856-024-00450-w. Commun Med (Lond). 2024. PMID: 38499690 Free PMC article.
-
Prevention of Protease-Induced Degradation of Desmoplakin via Small Molecule Binding.J Pers Med. 2024 Jan 31;14(2):163. doi: 10.3390/jpm14020163. J Pers Med. 2024. PMID: 38392596 Free PMC article.
-
Arrhythmogenic Cardiomyopathy: Definition, Classification and Arrhythmic Risk Stratification.J Clin Med. 2024 Jan 14;13(2):456. doi: 10.3390/jcm13020456. J Clin Med. 2024. PMID: 38256590 Free PMC article. Review.
References
-
- Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384–398. - PubMed
-
- Corrado D, Link MS, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med. 2017;376:61–72. - PubMed
-
- Marcus FI, Fontaine GH, Frank R, Gallagher JJ, Reiter MJ. Long-term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J. 1989;10(Supplement D):68–73. - PubMed
-
- Marcus FI. Update of arrhythmogenic right ventricular dysplasia. Card Electrophysiol Rev. 2002;6:54–56. - PubMed
-
- Marcus FI, Abidov A. Arrhythmogenic right ventricular cardiomyopathy 2012: diagnostic challenges and treatment. J Cardiovasc Electrophysiol. 2012;23:1149–1153. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous